Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 17

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
Item 1.    Financial Statements.

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (unaudited)

(in millions)

March 31,2025December 31,2024ASSETSCurrent assets:Cash and cash equivalents$91.8 $102.4 Trade accounts receivable120.4 121.2 Inventory28.3 27.5 Prepaid taxes14.3 16.4 Prepaid expenses and other current assets32.4 30.5 Total current assets287.2 298.0 Operating lease right-of-use assets53.4 55.0 Property, plant, and equipment, net114.0 117.4 Intangibles, net257.5 262.4 Goodwill286.3 286.3 Other assets7.7 8.5 Total assets$1,006.1 $1,027.6 LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$28.1 $32.3 Accrued liabilities112.1 119.0 Current maturities of operating lease liabilities10.9 12.8 Total current liabilities151.1 164.1 Unrecognized tax benefits1.4 32.7 Long-term debt59.3 39.6 Noncurrent operating lease liabilities87.4 87.9 Other long-term liabilities2.0 2.2 Total liabilities301.2 326.5 Commitments and contingenciesStockholders’ equity:Common stock, 92.2 and 91.3 shares outstanding at March 31, 2025 and December 31, 2024, respectively0.9 0.9 Additional paid-in capital1,461.5 1,457.8 Accumulated other comprehensive loss(0.6)(0.8)Accumulated deficit(756.9)(756.8)Total stockholders' equity704.9 701.1 Total liabilities and stockholders’ equity$1,006.1 $1,027.6 

See accompanying notes to Condensed Consolidated Financial Statements.

4

Table of Contents

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (unaudited)

(in millions, except per share